US House Republican leader blasts PhRMA on healthcare reform deal
This article was originally published in Scrip
US House Republican leader John Boehner of Ohio has penned a harsh letter to PhRMA president and CEO Billy Tauzin criticising the group's "short-sighted deal" with the White House for $80 billion in Medicare prescription drug savings over 10 years. The deal essentially endorses a federal takeover of healthcare and will not protect the interests of pharmaceutical companies or their employees from government intervention, Mr Boehner said.
You may also be interested in...
With inspectors no longer out in the field, they have more time to wrap up work on previously completed facility evaluations, attorney Howard Sklamberg says; inspections freeze could delay manufacturers’ abilities to bring facilities into compliance following adverse inspection findings, as well as agency reclassifications of facility status.
Experience and data from the study, which will use the same vector platform to deliver different transgenes for different diseases, could feed into the US FDA’s efforts to establish a public-private partnership to enable manufacturing of gene therapies for ultra-rare diseases.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.